Establishing the Rationale for ADC and ICI Combinations in TNBC

September 22, 2025

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Virginia Kaklamani, MD, DSc, and Tiffany A. Traina, MD, FASCO, discuss the rationale for and data to support combining TROP2-targeting antibody-drug conjugates (ADCs) with immune checkpoint inhibitors (ICIs) to treat triple-negative breast cancer (TNBC).

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Describe the mechanistic rationale for utilizing ADCs to target TROP2 in the management of patients with metastatic TNBC
Evaluate recent evidence supporting the evolving role of ADCs in the management of patients with metastatic TNBC

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Faculty:

Virginia Kaklamani, MD, DSc

Professor of Medicine
Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
A.B. Alexander Distinguished Chair in Oncology
Leader, Breast Oncology Program
UT Health San Antonio
The University of Texas MD Anderson Cancer Center
San Antonio, TX

Disclosures: Grant/Research Support: Eisai; Consultant: AstraZeneca, Genentech, Gilead, Lilly, Menarini, Pfizer; Speaker: AstraZeneca, Daichii Sankyo, Gilead.

Tiffany A. Traina, MD, FASCO

Associate Professor of Medicine
Weill Cornell Medicine
Associate Attending Physician
Vice Chair, Oncology
Department of Medicine
Section Head, Triple Negative Breast Cancer Clinical Research Program
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant/Research Support: Astellas Pharma, AstraZeneca, Ayala Pharmaceuticals, Daiichi Sankyo, Genentech/Roche, Pfizer; Consultant: AstraZeneca, Biotheranostics, Daiichi Sankyo, Exact Sciences, G1 Therapeutics, Genentech/Roche, Gilead Sciences, GSK, Hengrui Pharmaceuticals, Merck, Novartis, Pfizer, Stemline Therapeutics, TerSera.

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on how ADC plus ICI combinations are poised to change the landscape of TNBC treatment, go to https://www.gotoper.com/courses/establishing-the-rationale-for-adc-and-ici-combinations-in-tnbc.

Release Date

September 22, 2025

Expiration Date

September 22, 2026

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.